Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis
Condition: Ulcerative Colitis Interventions: Drug: CU104; Drug: Placebo Sponsor: Curacle Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 18, 2023 Category: Research Source Type: clinical trials
Skyrizi Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients
NORTH CHICAGO, Ill., June 15, 2023. AbbVie today announced positive top-line results from COMMAND, its Phase 3 maintenance study, showing risankizumab (SKYRIZI, 180 mg or 360 mg subcutaneous [SC]) achieved the primary endpoint of clinical remission... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 15, 2023 Category: Pharmaceuticals Source Type: clinical trials
The Application of Transcriptomics in the Treatment of Ulcerative Colitis With Ustekinumab
Condition: Ulcerative Colitis Intervention: Drug: Ustekinumab Sponsor: Evangelismos Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2023 Category: Research Source Type: clinical trials
Exploratory Clinical Trial of Safety and Efficacy of Sacral Nerve Stimulation in Patients With Ulcerative Colitis.
Condition: Ulcerative Colitis Intervention: Device: G132 system, Beijing PINS Medical Co., China Sponsor: Xijing Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2023 Category: Research Source Type: clinical trials
